Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Ecnoglutide: Evidence Summary
Evidence summary for Ecnoglutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Ecnoglutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Obesity/weight loss | Tier B | 1 | Phase 3 RCT showed superior weight reduction vs placebo |
| Type 2 diabetes | Tier B | 2 | Phase 3 RCTs vs placebo and vs dulaglutide |
References (2)
- Ecnoglutide for weight reduction in adults with overweight or obesity: Phase 3 trial — Sciwind Biosciences Investigators . Lancet Diabetes & Endocrinology (2025) PMID: 40555243
- Ecnoglutide vs dulaglutide in Type 2 diabetes: 52-week Phase 3 trial (EECOH-2) — Sciwind Biosciences Investigators . Lancet Diabetes & Endocrinology (2025)